Intraocular inflammation occurred more frequently with 8-mg aflibercept (Eylea) compared with what was observed in previous ...

Aflibercept 8 mg demonstrated sustained functional and anatomic improvements in patients with wet age-related macular degeneration through 156 weeks, according to a presenter.

The analysis included 41 patients who were treated with 136 intravitreal aflibercept, 8mg, injections. HealthDay News — The incidence of mild intraocular inflammation (IOI) in the real world ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

This trial demonstrated that aflibercept on a PRN basis maintained visual gains achieved in the first 6 months of treatment over a period of 18 months. [46] The data also demonstrated the efficacy ...

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

The trial met its primary endpoint, showing competitive efficacy and safety profiles for IBI302 compared to aflibercept.

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping ...

The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of ...